Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 3
1950 1
1951 1
1956 1
1957 1
1958 1
1959 1
1961 5
1962 2
1963 4
1964 4
1965 3
1966 10
1967 7
1968 11
1969 6
1970 6
1971 9
1972 12
1973 16
1974 7
1975 10
1976 15
1977 13
1978 12
1979 11
1980 3
1981 5
1982 8
1983 12
1984 10
1985 17
1986 15
1987 15
1988 16
1989 15
1990 11
1991 28
1992 32
1993 30
1994 30
1995 31
1996 28
1997 46
1998 41
1999 40
2000 64
2001 67
2002 61
2003 67
2004 97
2005 109
2006 124
2007 131
2008 170
2009 206
2010 244
2011 274
2012 335
2013 408
2014 453
2015 478
2016 504
2017 515
2018 551
2019 584
2020 696
2021 815
2022 554
Text availability
Article attribute
Article type
Publication date

Search Results

7,246 results
Results by year
Filters applied: . Clear all
Page 1
Omeprazole.
Shah N, Gossman W. Shah N, et al. 2022 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. 2022 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–. PMID: 30969608 Free Books & Documents.
CAR T-cell therapy for secondary CNS DLBCL.
Ahmed G, Hamadani M, Shah NN. Ahmed G, et al. Among authors: shah nn. Blood Adv. 2021 Dec 28;5(24):5626-5630. doi: 10.1182/bloodadvances.2021005292. Blood Adv. 2021. PMID: 34551065 Free PMC article.
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer.
Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, Ellis L, Alaiwi SA, Seo JH, Baca S, Beltran H, Khani F, Pomerantz M, Dall'Agnese A, Crowdis J, Van Allen EM, Bellmunt J, Morrisey C, Nelson PS, DeCaprio J, Farago A, Dyson N, Drapkin B, Liu XS, Freedman M, Haffner MC, Corey E, Brown M, Long HW. Cejas P, et al. Among authors: shah n. Nat Commun. 2021 Oct 1;12(1):5775. doi: 10.1038/s41467-021-26042-z. Nat Commun. 2021. PMID: 34599169 Free PMC article.
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days.
Mikkilineni L, Yates B, Steinberg SM, Shahani SA, Molina JC, Palmore T, Lee DW, Kaplan RN, Mackall CL, Fry TJ, Gea-Banacloche J, Jerussi T, Nussenblatt V, Kochenderfer JN, Shah NN. Mikkilineni L, et al. Among authors: shah nn. Blood Adv. 2021 Dec 14;5(23):5312-5322. doi: 10.1182/bloodadvances.2021004896. Blood Adv. 2021. PMID: 34619768 Free PMC article. Review.
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Ciampricotti M, Chow A, Offin M, Ray-Kirton J, Egger JD, Bhanot UK, Linkov I, Asher M, Roehrl MH, Ventura K, Qiu J, de Stanchina E, Chang JC, Rekhtman N, Houck-Loomis B, Koche RP, Yu HA, Sen T, Rudin CM. Quintanal-Villalonga A, et al. Among authors: shah ns. J Hematol Oncol. 2021 Oct 16;14(1):170. doi: 10.1186/s13045-021-01186-z. J Hematol Oncol. 2021. PMID: 34656143 Free PMC article.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüßmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P. Wilson MR, et al. Among authors: shah n. Blood. 2022 Apr 21;139(16):2499-2511. doi: 10.1182/blood.2021014506. Blood. 2022. PMID: 34995350
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL.
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench D, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend W. Northend M, et al. Among authors: shah n. Blood Adv. 2022 May 10;6(9):2920-2926. doi: 10.1182/bloodadvances.2021005953. Blood Adv. 2022. PMID: 35020818 Free PMC article. No abstract available.
7,246 results